The Breakthrough Therapy Designation and strong cash position significantly de-risk the path to Phase 3 in MASH. Traders should monitor upcoming topline data from the AUD trial in Q3 2026, which could serve as a secondary catalyst.
Price Chart
Executive Summary
Altimmune reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balance sheet with $274 million in cash as of December 31, 2025, and $340 million as of February 28, 2026, following a $75 million registered direct offering. The company announced FDA Breakthrough Therapy Designation for pemvidutide in MASH and plans to initiate a Phase 3 trial in 2026, while expecting topline data from its Phase 2 AUD trial in Q3 2026.
Key Financial Metrics
Key Facts
- FDA granted Breakthrough Therapy Designation for pemvidutide in MASH based on 24-week IMPACT trial data
- Cash, cash equivalents, and short-term investments totaled $274 million as of December 31, 2025, up from $132 million a year prior
- Raised $75 million via registered direct offering and $8 million via ATM in January 2026, bringing total cash to ~$340 million by February 28, 2026
- Net loss narrowed to $27.4 million in Q4 2025 vs. $23.2 million in Q4 2024; full-year net loss decreased to $88.1 million from $95.1 million
- Phase 3 trial in MASH planned for initiation in 2026; topline data from Phase 2 AUD trial expected in Q3 2026
Financial Impact
Cash position increased by ~107% year-over-year; $83 million raised in early 2026 strengthens runway for Phase 3 development
Risk Factors
- Biotech clinical-stage risk: future trial results may not replicate prior success
- Dilution from recent $83 million in equity raises may weigh on shares despite strengthening balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers